Researchers have shown for the first time in an animal that is more closely related to humans that it is possible to make new bone from stem-cell-like induced pluripotent stem cells (iPSCs) made from an individual animal's own skin cells.
The study in monkeys also shows that there is some risk that those iPSCs could seed tumours, but that outcome appears to be less likely than studies in immune-compromised mice would suggest.
"We have used this model to demonstrate that tumour formation of a type called a 'teratoma' from undifferentiated autologous iPSCs does occur; however, tumour formation is very slow and requires large numbers of iPSCs given under very hospitable conditions. We have also shown that new bone can be produced from autologous iPSCs, as a model for their possible clinical application," said Cynthia.
That means that use of these cells in tissue repair would not require long-term or possibly toxic immune suppression drugs to prevent rejection.
Researchers first used a standard recipe to reprogramme skin cells taken from rhesus macaques. They then coaxed those cells to form first pluripotent stem cells and then cells that have the potential to act more specifically as bone progenitors.
Those progenitor cells were then seeded onto ceramic scaffolds that are already in use by reconstructive surgeons attempting to fill in or rebuild bone. And, it worked; the monkeys grew new bone, researchers said.
In other experiments, undifferentiated iPSCs did form teratomas in a dose-dependent manner.
The researchers say that therapies based on this approach could be particularly beneficial for people with large congenital bone defects or other traumatic injuries.
Although bone replacement is an unlikely "first in human" use for stem cell therapies given that the condition it treats is not life threatening, the findings in a primate are an essential step on the path towards regenerative clinical medicine.
The study was published in the journal Cell Reports.
You’ve reached your limit of 10 free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹810
1 Year
₹67/Month
Super Saver
₹1,170
2 Years
₹48/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories
Over 30 subscriber-only stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app